Boron Neutron Capture Therapy

Name: Boron Neutron Capture Therapy
Brand: Springer Nature
SKU: 9781461534082
Availability: InStock

Best Price:
Buy Boron Neutron Capture Therapy for $39.99 at @ Link.springer.com
No coupon is required — this is the standard retail price.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $39.99 - $39.99

BEST PRICE

Single Product Purchase

$39.99

@ Link.springer.com BUY Now

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$39.99	$39.99			$39.99		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9781461534082

Condition

New

Product Description

The European Collaboration on Boron Neutron Capture Therapy (BNCT), conceived in 1987 and successful in 1989 in gaining financial support as a Concerted Action through the Medical and Health Research Programme of the Commission ofthe European Communities (CEC) in Brussels, considered it an opportune moment to hold its annual Plenary Meeting on 18-20 Septem ber 1991 as an International Workshop entitled "Towards Clinical Trials of Glioma with BNCT". The background to this consideration was influenced by the world-wide resurgence ofinterest in NCT over the last 2 decades and by the exemplifica tions at the Fourth International Symposium on Neutron Capture Therapy for Cancer held in Sydney in December 1990, where it was strongly indicated that within the next 2 years clinical trials would be started both in Europe and the United States. In particular at the High Flux Reactor of the Joint Research Centre of the CEC at Petten in The Netherlands, an epithermal neutron beam designed and installed in the summer of 1990 recently became operable at full reactor power. An extensive series ofexperiments, including the nuclear and radiobiological characterisation of the beam and a healthy tissue tolerance study on canines has started and has the aim to define the preconditions for clinical trials onpatients with Grade III/IV glioma. However, as with any other new therapy modality, it must be demon strated that BNCT is safe for the patient and has a reasonable chance of being an effective therapy.

Available Colors

N/A

Available Sizes

N/A